Takeda: cell cultures beat eggs for vaccine manufacture

By Fiona BARRY

- Last updated on GMT

Picture credit: Flickr/Maria
Picture credit: Flickr/Maria

Related tags: Influenza, Vaccine

Cell cultures outshine traditional chicken eggs for vaccine manufacture, especially during a pandemic, Takeda has told BioPharma-Reporter.com.

The pharmaceutical giant has received New Drug Application (NDA) approval from the Japanese Ministry of Health, Labour and Welfare to manufacture and supply a cell-cultured pandemic influenza vaccine in the event of an outbreak.

‘Surge capacity’

Takeda’s vaccines spokesman said that, unlike traditional hens egg-based production technologies, cell lines allow fast production of vaccines in emergencies.

The development and production of vaccines can be shorter in cell culture systems, and do not depend on a standing supply of chicken flocks and eggs – which themselves may be threatened by a pandemic virus,​” said Tarsis Lopez, Senior Manager, Vaccine Communications, Takeda.

Cell culture systems can be scaled up rapidly, responding to the ‘surge capacity’ needs of a pandemic, which require large quantities of vaccine to be produced in a very short period of time,​” he continued.

Japanese rival Daiichi said last month is would be “impossible​” for it to meet Japan’s emergency pandemic plan of 50m vaccines, due to problems​ at an antigen production plant.

The technology has other advantages over eggs for vaccine manufacture, Lopez told us. “Some pandemic viruses originate in birds and can be difficult to grow in eggs – cell culture technology circumvents this problem.​”

Additionally, cell culture-derived vaccines can be administered to people with egg allergies, he said.

Baxter partnership

The newly approved vaccine, named “Cell Cultured Influenza vaccine H5N1 TAKEDA 1mL​,” uses Vero cell technology​ licensed from Baxter International, which announced last month it plans to separate its biopharma business​ from its medical products company.

The influenza vaccine will be manufactured at a new facility for cell culture-based influenza vaccines subsidised by the Japanese government in Takeda’s Hikari Plant.

In the event of an outbreak the vaccine is intended to be injected intramuscularly or subcutaneously in two 0.5ml doses with an interval of three weeks or longer.

Related topics: Upstream Processing, Cell lines

Related news

Show more

Related products

Connectivity & Integration in Biomanufacturing

Connectivity & Integration in Biomanufacturing

Wheeler Bio | 17-Nov-2022 | Technical / White Paper

As the Pharma 4.0 initiative sets a new industry paradigm, more biomanufacturing companies are asking how they can design and build facilities that apply...

Scalability, Quality, and Speed with Transposons

Scalability, Quality, and Speed with Transposons

Wheeler Bio | 20-Oct-2022 | Technical / White Paper

To solve for the significant bottlenecks often presented by conventional cell line development processes, this article discusses how Wheeler Bio is leveraging...

Accelerating Time to IND with Pharma 4.0

Accelerating Time to IND with Pharma 4.0

Wheeler Bio | 22-Sep-2022 | Technical / White Paper

The future of the biopharmaceutical industry hinges on its adoption of 21st-century digital tools and automation.

Discover the world of upstream bioprocessing

Discover the world of upstream bioprocessing

Eppendorf Bioprocess Solutions | 07-Sep-2022 | Technical / White Paper

A must-read for all bioprocess scientists: This bundle of four ebooks created by Eppendorf guides you through the world of upstream bioprocessing.

Related suppliers

Follow us

Products

View more

Webinars